These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36201195)

  • 1. The Male to Female Ratio in Treatment-Warranted Retinopathy of Prematurity: A Systematic Review and Meta-analysis.
    Hoyek S; Peacker BL; Acaba-Berrocal LA; Al-Khersan H; Zhao Y; Hartnett ME; Berrocal AM; Patel NA
    JAMA Ophthalmol; 2022 Nov; 140(11):1110-1120. PubMed ID: 36201195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
    Sankar MJ; Sankar J; Chandra P
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD009734. PubMed ID: 29308602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
    Sankar MJ; Sankar J; Mehta M; Bhat V; Srinivasan R
    Cochrane Database Syst Rev; 2016; 2():CD009734. PubMed ID: 26932750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Network Meta-Analysis of Retreatment Rates following Bevacizumab, Ranibizumab, Aflibercept, and Laser for Retinopathy of Prematurity.
    Chang E; Josan AS; Purohit R; Patel CK; Xue K
    Ophthalmology; 2022 Dec; 129(12):1389-1401. PubMed ID: 35842190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulmonary Hypertension in Preterm Infants Treated With Laser vs Anti-Vascular Endothelial Growth Factor Therapy for Retinopathy of Prematurity.
    Nitkin CR; Bamat NA; Lagatta J; DeMauro SB; Lee HC; Patel RM; King B; Slaughter JL; Campbell JP; Richardson T; Lewis T
    JAMA Ophthalmol; 2022 Nov; 140(11):1085-1094. PubMed ID: 36201183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and ocular safety following aflibercept, conbercept, ranibizumab, bevacizumab, and laser for retinopathy of prematurity: a systematic review and meta-analysis.
    Chen J; Hao Q; Zhang J; Du Y; Chen H; Cheng X
    Ital J Pediatr; 2023 Oct; 49(1):136. PubMed ID: 37814332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey.
    Gunay M; Sukgen EA; Celik G; Kocluk Y
    Curr Eye Res; 2017 Mar; 42(3):462-469. PubMed ID: 27420302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retinal Detachment after Treatment of Retinopathy of Prematurity with Laser versus Intravitreal Anti-Vascular Endothelial Growth Factor.
    Barry GP; Yu Y; Ying GS; Tomlinson LA; Lajoie J; Fisher M; Binenbaum G;
    Ophthalmology; 2021 Aug; 128(8):1188-1196. PubMed ID: 33387554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beta-blockers for prevention and treatment of retinopathy of prematurity in preterm infants.
    Kaempfen S; Neumann RP; Jost K; Schulzke SM
    Cochrane Database Syst Rev; 2018 Mar; 3(3):CD011893. PubMed ID: 29499081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Intravitreal Aflibercept vs Laser Photocoagulation on Treatment Success of Retinopathy of Prematurity: The FIREFLEYE Randomized Clinical Trial.
    Stahl A; Sukgen EA; Wu WC; Lepore D; Nakanishi H; Mazela J; Moshfeghi DM; Vitti R; Athanikar A; Chu K; Iveli P; Zhao F; Schmelter T; Leal S; Köfüncü E; Azuma N;
    JAMA; 2022 Jul; 328(4):348-359. PubMed ID: 35881122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reactivation of retinopathy of prematurity after ranibizumab treatment.
    Wong RK; Hubschman S; Tsui I
    Retina; 2015 Apr; 35(4):675-80. PubMed ID: 25768252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurodevelopmental Outcomes after Bevacizumab Treatment for Retinopathy of Prematurity: A Meta-analysis.
    Tsai CY; Yeh PT; Tsao PN; Chung YE; Chang YS; Lai TT
    Ophthalmology; 2021 Jun; 128(6):877-888. PubMed ID: 33212122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity: A Randomized Clinical Trial.
    Stahl A; Krohne TU; Eter N; Oberacher-Velten I; Guthoff R; Meltendorf S; Ehrt O; Aisenbrey S; Roider J; Gerding H; Jandeck C; Smith LEH; Walz JM;
    JAMA Pediatr; 2018 Mar; 172(3):278-286. PubMed ID: 29309486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison in Retreatments between Bevacizumab and Ranibizumab Intravitreal Injections for Retinopathy of Prematurity: A Multicenter Study.
    Patel NA; Acaba-Berrocal LA; Hoyek S; Fan KC; Martinez-Castellanos MA; Baumal CR; Harper CA; Berrocal AM;
    Ophthalmology; 2023 Apr; 130(4):373-378. PubMed ID: 36396121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy comparison of anti-vascular endothelial growth factor drugs for the treatment of type 1 retinopathy of prematurity: A network meta-analysis of randomised controlled trials.
    Zhou M; Hashimoto K; Liu W; Cai Y; Liang J; Shi X; Zhao M
    Graefes Arch Clin Exp Ophthalmol; 2024 May; 262(5):1409-1419. PubMed ID: 37815595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Use of Postnatal Weight Gain Algorithms to Predict Severe or Type 1 Retinopathy of Prematurity: A Systematic Review and Meta-analysis.
    Athikarisamy S; Desai S; Patole S; Rao S; Simmer K; Lam GC
    JAMA Netw Open; 2021 Nov; 4(11):e2135879. PubMed ID: 34812847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants.
    Ohlsson A; Aher SM
    Cochrane Database Syst Rev; 2006 Jul; (3):CD004863. PubMed ID: 16856062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of refractive error in children treated for retinopathy of prematurity with anti-vascular endothelial growth factor (anti-VEGF) agents: A meta-analysis and systematic review.
    Tan QQ; Christiansen SP; Wang J
    PLoS One; 2019; 14(12):e0225643. PubMed ID: 31790445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis.
    Hwang CK; Hubbard GB; Hutchinson AK; Lambert SR
    Ophthalmology; 2015 May; 122(5):1008-15. PubMed ID: 25687024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.